Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alkem Laboratories Ltd

ALKEM.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: BUY

Last Close

$54.93

▼ -0.06%

Market Cap $6.57B · Vol 63.26K

Key Metrics

P/E Ratio

28.76

FWD: 25.32

Market Cap

$6.57B

Mid Cap

Div Yield

1.02%

Semi-annual dividend

EPS Growth

-7.42%

YoY

RSI (14)

33.57

Momentum

Beta

0.77

vs Market

52W High

$62.80

16.88% below

52W Low

$53.72

1.84% above

Volume

63.26K

Avg 127.87K

P/B

4.58

Price-to-book

ROE

19.19%

Return on equity

Free Float

37.56%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Alkem Laboratories Ltd (ALKEM.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ALKEM.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.08%

-7.45%

-1.64%

-5.06%

YTD

-5.75%

-2.10%

+25.10%

+36.37%

Financials & Valuation

TTM · Annual

Total Revenue	$1.57B
Net Income	$251.58M
Revenue Growth (YoY)	+10.95%
Gross Margin	61.40%
Operating Margin	18.34%
Net Profit Margin	15.98%
ROE	19.19%
ROA · ROIC	14.88% · 15.76%

P/E Ratio	28.76
Forward P/E (FY1)	25.32
PEG Ratio	4.37
P/S	4.31
P/B	4.58
P/FCF	40.88
EPS Growth	-7.42%
Outstanding Shares	119.57M

Technical Indicators

50-Day SMA	$58.46
200-Day SMA	$58.48
RSI (14)	33.57
Beta	0.77
52-Week High	$62.80
52-Week Low	$53.72

Volume Today	63.26K
Avg Daily Volume (30D)	127.87K
Relative Volume	0.49x
Volatility (10D)	11.15
Volatility (30D)	16.72
Free Float	37.56%

Analyst Consensus

BUY

Current Price $54.93

Mean Target $62.70

52W Low$53.72 52W High$62.80

Current

Target

$53.72 $62.80

Current Analyst target

+14.13% upside potential · 21 analysts

Identifiers

ExchangeNSE India

FIGIBBG001TTNSZ7

ISININE540L01014

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -0.88% JNJ Johnson & Johnson -1.15% ABBV Abbvie Inc -1.44% NVS Novartis AG -1.90% NOVN.S Novartis AG -1.33%

Company Profile

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.